LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Akebia Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

3.64 -2.67

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.59

Max

3.74

Galvenie mērījumi

By Trading Economics

Ienākumi

29M

6.1M

Pārdošana

11M

57M

EPS

0.025

Peļņas marža

10.66

Darbinieki

181

EBITDA

20M

14M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+90.22% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

345M

956M

Iepriekšējā atvēršanas cena

6.31

Iepriekšējā slēgšanas cena

3.64

Ziņu noskaņojums

By Acuity

49%

51%

157 / 380 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Akebia Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 27. jūn. 20:51 UTC

Peļņas

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025. g. 27. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 27. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 27. jūn. 20:48 UTC

Tirgus saruna

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

2025. g. 27. jūn. 20:46 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 27. jūn. 20:46 UTC

Tirgus saruna

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

2025. g. 27. jūn. 19:31 UTC

Tirgus saruna

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

2025. g. 27. jūn. 19:19 UTC

Tirgus saruna

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

2025. g. 27. jūn. 19:16 UTC

Tirgus saruna

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025. g. 27. jūn. 18:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 27. jūn. 18:42 UTC

Tirgus saruna

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

2025. g. 27. jūn. 18:39 UTC

Tirgus saruna
Peļņas

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

2025. g. 27. jūn. 18:29 UTC

Tirgus saruna

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

2025. g. 27. jūn. 18:18 UTC

Tirgus saruna

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

2025. g. 27. jūn. 18:16 UTC

Tirgus saruna

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

2025. g. 27. jūn. 17:16 UTC

Tirgus saruna

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

2025. g. 27. jūn. 17:08 UTC

Peļņas

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

2025. g. 27. jūn. 16:52 UTC

Iegādes, apvienošanās, pārņemšana

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

2025. g. 27. jūn. 16:22 UTC

Peļņas

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025. g. 27. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 27. jūn. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 27. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 27. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 27. jūn. 15:59 UTC

Tirgus saruna

Gold Futures Slump on Improving Risk Appetite -- Market Talk

2025. g. 27. jūn. 15:56 UTC

Tirgus saruna

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Salīdzinājums

Cenas izmaiņa

Akebia Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

90.22% augšup

Prognoze 12 mēnešiem

Vidējais 7 USD  90.22%

Augstākais 8 USD

Zemākais 6 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Akebia Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

3

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

2.345 / N/AAtbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

157 / 380 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.